Growth Hormone: A Literature Course in Six Modules

Growth hormone (GH, also called somatotropin) is described in physiology reviews as a polypeptide hormone secreted by somatotroph cells of the anterior pituitary gland under hypothalamic control (PMID 29489209). The phrase "growth hormone peptide" is used loosely online, so this course begins with a distinction: GH itself is a pituitary protein hormone, and the literature cited here concerns GH, its receptor, and recombinant GH used in deficiency states, not the separate category of synthetic secretagogue peptides sold for laboratory use.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or treatment decision. Nothing below is a protocol, and no dose is listed, because the verified sources summarised here do not report dosing regimens within the scope of their titles and abstracts.

Module 1: What Growth Hormone Is and How It Has Been Studied

Definition, class and origin

Physiology reviews classify GH as a single-chain polypeptide hormone of anterior pituitary origin, released in pulses and regulated by hypothalamic releasing and inhibiting signals (PMID 29489209). A review of the hormonal regulation of childhood growth placed GH within a wider endocrine network, describing growth as the output of GH, insulin-like growth factor 1 (IGF-1), thyroid hormone, sex steroids and nutritional signals acting together rather than of GH alone (PMID 28437784).

Forms encountered in the literature

• Endogenous pituitary GH — the hormone as secreted, studied through physiology reviews and secretion studies (PMID 29489209).
• Recombinant human GH used as replacement — reviews of adult growth hormone deficiency described replacement therapy across the transition from paediatric to adult care and into later life (PMID 30378784), and a 2024 management article addressed continuation and re-evaluation of treatment specifically in the transition period (PMID 38557372).
• GH as a doping agent — a 2023 sports endocrinology review grouped GH with IGF-1, insulin and erythropoietin as hormones misused in sport (PMID 36736729).

How the evidence base was built

The verified literature behind this course spans four study types: narrative and physiology reviews (PMID 29489209, PMID 28437784), clinical management reviews of deficiency states (PMID 30378784, PMID 38557372), mechanistic and genetic laboratory work such as the 2023 chapter on growth hormone receptor gene disruption (PMID 37717983), and single-patient reports, including a 2020 case of hypothalamic lipoma associated with growth hormone deficiency (PMID 32042280).

Limits of the evidence in Module 1

Definitional sources are reviews and reference chapters, not primary experiments, so they summarise consensus rather than test it. None of the cited definitional sources evaluated synthetic secretagogue peptides, and the case report on hypothalamic lipoma describes one patient, which cannot establish how often such lesions cause deficiency (PMID 32042280).

Module 2: Mechanism as Described in the Literature

The hypothalamic–pituitary–IGF-1 axis

Physiology reviews described GH release as pulsatile and under dual hypothalamic control, with downstream effects mediated in large part by IGF-1 generated in the liver and peripheral tissues (PMID 29489209). The childhood growth review framed the same axis developmentally, describing how GH and IGF-1 signalling interact with the growth plate and with other hormonal inputs during different phases of growth (PMID 28437784).

Receptor-level mechanism

A 2023 chapter reviewed what disruption of the growth hormone receptor gene has revealed, describing global and tissue-specific receptor-disrupted mouse lines and the metabolic and growth phenotypes researchers reported in them (PMID 37717983). That body of work is the main reason receptor-level signalling, rather than circulating GH concentration alone, is treated in the literature as the determinant of tissue response (PMID 37717983).

Sleep-coupled secretion

A 2025 study published in Cell described a neuroendocrine circuit through which sleep state was coupled to growth hormone release, and the researchers reported that sleep-dependent GH secretion depended on identified circuit elements rather than occurring as a passive consequence of rest (PMID 40562026). This added a circuit-level account to the older observation, repeated in physiology reviews, that GH pulses cluster during sleep (PMID 29489209).

Actions described outside growth

A 2020 review in Vitamins and Hormones examined GH and synaptogenesis, summarising experimental evidence that GH signalling influenced synapse formation and neural plasticity in the nervous system (PMID 32723552). A 2019 review of growth hormone and endometrial receptivity described GH signalling within endometrial tissue and the rationale investigators gave for studying GH in reproductive medicine (PMID 31616379).

Limits of the evidence in Module 2

Mechanistic claims rest heavily on animal and cell work. The receptor-disruption literature was generated in mice and the chapter itself is a review of those models (PMID 37717983), and the synaptogenesis review summarised experimental systems rather than human outcomes (PMID 32723552). Circuit mapping of sleep-dependent release describes physiology, not the effect of administered hormone (PMID 40562026).

Module 3: Reported Outcomes by Study

The table below summarises what each cited source studied and what it reported, in the authors' own framing. No efficacy promise is implied; several entries are reviews, which aggregate prior findings rather than generate new ones.

Limits of the evidence in Module 3

Most entries are reviews, so their conclusions inherit the weaknesses of the underlying trials, including small sample sizes and heterogeneous endpoints. The aging review presented the significance of falling GH output as unresolved rather than settled (PMID 36948778), and the endometrial receptivity review discussed GH in an investigational rather than established role (PMID 31616379). None of these sources support a general performance or anti-aging benefit claim.

Module 4: Growth Hormone Side Effects: What Studies Report

Adverse events in this literature come from two very different contexts: supervised replacement in diagnosed deficiency, and unsupervised misuse.

Adverse events in the misuse context

The 2023 sports endocrinology review addressed GH alongside IGF-1, insulin and erythropoietin and described the health risks associated with their misuse by athletes, together with the analytical difficulty of detecting them (PMID 36736729). The same review emphasised that hormones obtained outside medical supervision carry risk profiles that were not characterised in approved-indication trials (PMID 36736729).

Safety considerations in replacement and in older adults

The 2023 review of growth hormone and aging discussed why GH administration in older adults has remained controversial, weighing physiological rationale against safety concerns raised in the literature (PMID 36948778). Reviews of adult growth hormone deficiency described monitoring and periodic re-evaluation as part of management rather than optional, reflecting the need to track response and tolerability over time (PMID 30378784), and the 2024 transition-period management article likewise built retesting and follow-up into its framework (PMID 38557372).

What receptor-disruption models suggested

The receptor gene disruption chapter reported that removing GH signalling altered growth and metabolic phenotypes in mice, which is the mirror image of the concern that excess signalling shifts the same parameters (PMID 37717983).

Limits of the evidence in Module 4

No frequency figures are given here because the cited sources are reviews and reference works that discussed risk qualitatively within their abstract scope rather than reporting incidence rates (PMID 36736729, PMID 36948778). Safety data from deficiency populations under physician supervision cannot be extrapolated to people with normal GH axes, and misuse-context reports rely on self-reported exposure of unknown composition (PMID 36736729).

Module 5: Pharmacokinetics Where Data Exist

The verified sources for this course describe secretion kinetics more than administered-drug kinetics. Physiology reviews characterised endogenous GH as released in discrete pulses rather than at a steady concentration, which means a single blood measurement reflects pulse timing as much as total output (PMID 29489209). The 2025 circuit study reinforced that timing dimension by reporting that sleep state gated GH release through a defined neuroendocrine pathway (PMID 40562026).

Across the lifespan, the 2023 aging review described GH secretion as declining with advancing age, a trajectory often referred to in the literature as reduced somatotropic axis activity (PMID 36948778). Pulsatility and short-lived circulating presence are also why the sports endocrinology review discussed the analytical strategies used to detect GH and IGF-1 misuse, rather than simple single-sample measurement (PMID 36736729).

Limits of the evidence in Module 5

This module lists no half-life, no bioavailability figure and no dose, because none of the verified sources reports those parameters within the scope of their titles and abstracts. Readers should treat this as an absence of cited data here, not as evidence that such data do not exist elsewhere in the wider literature.

Module 6: Regulatory Status, Stated Factually

Recombinant human growth hormone (somatropin) is a prescription product approved in the United States and other jurisdictions for specified indications, and the clinical literature on growth hormone deficiency is written around that supervised, prescribed use (PMID 30378784, PMID 38557372). Under US federal law, distribution or possession of human growth hormone for uses other than those approved and authorised by a physician is separately restricted, which distinguishes GH from most other prescription drugs.

Materials labelled "research use only" are, by that label, not intended for human administration and are not reviewed for safety, purity or potency as human drugs. Compounded preparations sit in a third category: under US law, pharmacies compounding under sections 503A and 503B may only use bulk substances that meet defined eligibility criteria, and the eligibility of many peptide substances has been the subject of regulatory review. In sport, GH falls under anti-doping regulation, and the 2023 review described it as one of the hormones targeted by detection programmes (PMID 36736729).

This section describes publicly available regulatory facts and is not legal advice; rules differ by country and state and change over time.

Limits of the evidence in Module 6

Regulatory categories are administrative, not scientific: approval for one indication says nothing about outcomes in other populations, and the cited clinical reviews studied diagnosed deficiency rather than general use (PMID 30378784). None of the verified papers evaluated the quality, labelling accuracy or content of non-pharmaceutical material.

What the Studies Did Not Test

Reading the verified set together, several questions remain outside what was examined:

• Healthy-adult enhancement. The deficiency literature enrolled patients with diagnosed deficiency and addressed their management rather than augmentation in people with intact axes (PMID 30378784, PMID 38557372).
• Whether age-related decline should be treated. The aging review presented that question as unresolved rather than answered (PMID 36948778).
• Human translation of neural findings. The synaptogenesis review summarised experimental systems, not clinical cognitive endpoints (PMID 32723552), and the sleep-circuit study characterised physiology rather than any intervention (PMID 40562026).
• Long-term reproductive outcomes. The endometrial receptivity review discussed mechanism and investigational use rather than establishing live-birth outcomes (PMID 31616379).
• Generalisability of single cases. One hypothalamic lipoma report and one epilepsy-and-depression report describe specific clinical situations and were not designed to generalise (PMID 32042280, PMID 30773449).
• Non-pharmaceutical material. No cited study tested unapproved or research-labelled products, so nothing in this course speaks to them.

Growth hormone remains one of the most studied hormones in endocrinology, and the literature in this course is consistent on the basics — pituitary origin, pulsatile and sleep-linked release, receptor-mediated and IGF-1-mediated action — while being markedly less settled on questions of use beyond diagnosed deficiency (PMID 29489209, PMID 36948778). This page is educational only and is not medical advice; questions about individual health belong with a licensed physician.

References

• Physiology, Growth Hormone (StatPearls, 2026)
• The Physiology of Childhood Growth: Hormonal Regulation (Hormone Research in Paediatrics, 2017)
• Neuroendocrine circuit for sleep-dependent growth hormone release (Cell, 2025)
• Growth hormone receptor gene disruption (Vitamins and Hormones, 2023)
• Growth hormone (GH) and synaptogenesis (Vitamins and Hormones, 2020)
• Adult Growth Hormone Deficiency: from Transition to Senescence (Pediatric Endocrinology Reviews, 2018)
• Management of transition growth hormone deficiency (Chinese Journal of Contemporary Pediatrics, 2024)
• Growth Hormone and Aging (Endocrinology and Metabolism Clinics of North America, 2023)
• Doping and sports endocrinology: growth hormone, IGF-1, insulin, and erythropoietin (Revista Clinica Espanola, 2023)
• Growth Hormone and Endometrial Receptivity (Frontiers in Endocrinology, 2019)
• Epilepsy, depression, and growth hormone (Epilepsy & Behavior, 2019)
• Hypothalamic lipoma and growth hormone deficiency (International Journal of Pediatric Endocrinology, 2020)